NASDAQ: MGX
Metagenomi Inc Earnings Dates, Reports, Calls

Metagenomi earnings were -$77.9M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest MGX earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$25.0M, up 7% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, MGX reported annual earnings of -$78.1M, with 14.4% growth.

MGX earnings history

Current Revenue
$45.3M
Current Earnings
-$77.9M
Current Profit Margin
-172.2%

MGX Return on Equity

Current Company
-32.1%
Current Industry
-60.2%
Current Market
31.5%
MGX's Return on Equity (-32.1%)... subscribe to Premium to read more.
High Return on Equity Performance

MGX undefined

Current Company
-22.8%
Current Industry
-2.5%
MGX is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when MGX announces earnings.

MGX undefined

Current Company
-32.32%
Current Industry
5.8%

MGX vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
MGX-$73.08M-$77.95MN/A-$2.11
IFRX-$50.25M-$50.82MN/A-$0.85
CNTBN/AN/AN/AN/A
PRLD-$124.49M-$127.83MN/A-$1.69
ATRA$7.38M-$15.64MN/A-$2.57

Metagenomi Earnings Reports & History FAQ

What were Metagenomi's earnings last quarter?

Metagenomi (NASDAQ: MGX) reported Q1 2025 earnings per share (EPS) of -$0.68, up 42.86% year over year. Total MGX earnings for the quarter were -$25.04 million. In the same quarter last year, Metagenomi's earnings per share (EPS) was -$1.19.

If you're new to stock investing, here's how to buy Metagenomi stock.

Is Metagenomi profitable or losing money?

As of the last Metagenomi earnings report, Metagenomi is currently losing money. Metagenomi's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$77.95 million, a 0.88% increase year over year.

What was MGX's earnings growth in the past year?

As of Metagenomi's earnings date in Q2 2025, Metagenomi's earnings has grown year over year. MGX earnings in the past year totalled -$77.95 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.